Julie Meade

635 total citations · 1 hit paper
8 papers, 403 citations indexed

About

Julie Meade is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Julie Meade has authored 8 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Gastroenterology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Julie Meade's work include Gastrointestinal Tumor Research and Treatment (8 papers), Gastric Cancer Management and Outcomes (6 papers) and Gastrointestinal disorders and treatments (4 papers). Julie Meade is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (8 papers), Gastric Cancer Management and Outcomes (6 papers) and Gastrointestinal disorders and treatments (4 papers). Julie Meade collaborates with scholars based in United States, United Kingdom and Netherlands. Julie Meade's co-authors include Rodrigo Ruiz‐Soto, Hans Gelderblom, Margaret von Mehren, Robin L. Jones, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, Jean‐Yves Blay and Steven Attia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Julie Meade

8 papers receiving 402 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

2020 251 citations Jean‐Yves Blay, César Serrano et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Julie Meade

Since Specialization

Citations

This map shows the geographic impact of Julie Meade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Meade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Meade more than expected).

Fields of papers citing papers by Julie Meade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Meade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Meade. The network helps show where Julie Meade may publish in the future.

Co-authorship network of co-authors of Julie Meade

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Meade. A scholar is included among the top collaborators of Julie Meade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Meade. Julie Meade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial 2022 ·Journal of Clinical Oncology ·Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, (unknown), Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich	61
2	Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial 2022 ·BMC Cancer ·Patrick Schöffski, Suzanne George, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz‐Soto, Jean‐Yves Blay, Margaret von Mehren	4
3	Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor 2022 ·Clinical Pharmacology in Drug Development ·Xiaoyan Li, Mark Shelton, (unknown), Julie Meade, Rodrigo Ruiz‐Soto	7
4	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour 2021 ·European Journal of Cancer ·Suzanne George, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Albiruni Abdul Razak, Michael S. Gordon, Neeta Somaiah, (unknown), Julie Meade, Kelvin Shi, Ying Su, Rodrigo Ruiz‐Soto, Filip Jankú	22
5	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study 2021 ·Clinical Cancer Research ·Sebastian Bauer, Michael C. Heinrich, Suzanne George, John Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz‐Soto, Jean‐Yves Blay, Margaret von Mehren, Patrick Schöffski	33
6	Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies 2021 ·Cancer Research ·Suzanne George, Filip Jankú, Ping Chi, Margaret von Mehren, Neeta Somaiah, Hans Gelderblom, Robin L. Jones, (unknown), Adekemi Taylor, Xiaoyan Li, Julie Meade, (unknown), Rodrigo Ruiz‐Soto, Jing Wang, Michael C. Heinrich	2
7	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study 2021 ·The Oncologist ·John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Meade, (unknown), Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean‐Yves Blay	23
8	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial breakdown → 2020 ·The Lancet Oncology ·Jean‐Yves Blay, César Serrano, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz‐Soto, Suzanne George, Margaret von Mehren	251

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact